FDA Approves TECNIS PureSee IOL for Cataract Surgery - Summary - MDSpire
FDA & Government News

FDA Approves TECNIS PureSee IOL for Cataract Surgery

First FDA-approved extended depth of focus (EDOF) IOL maintaining contrast sensitivity comparable to an aspheric monofocal IOL

  • March 23, 2026

  • 2 min

Share

Johnson & Johnson has received FDA approval for TECNIS PureSee IOL, an innovative extended depth of focus intraocular lens designed for cataract surgery. This lens aims to enhance the visual experience for patients with cataracts, addressing not only cataract-related vision loss, but also the effects of presbyopia. Available later this year, the TECNIS PureSee IOL promises to offer high contrast sensitivity, minimizing reliance on glasses post-surgery, as revealed by positive patient feedback.

Original Source(s)

FDA Approves TECNIS PureSee IOL for Cataract Surgery

  • March 23, 2026

Related Content

Music May Ease Anxiety in Eye Clinics

Background music and multimedia exposure were associated with lower patient-reported anxiety in a quasi-experimental ophthalmology clinic study that used existing clinic audiovisual infrastructure at no additional cost.

Smoking Doubles Risk of Vision Loss

New research indicates smoking doubles the risk of multiple sight-threatening conditions

  • May 15, 2026

  • 3 min
Can Gene Therapy Deliver Durability?

At Retina World Congress, David A. Eichenbaum, MD, examined whether late-stage intravitreal gene therapies can reduce injection burden in nAMD.